BGI Genomics

03/06/2026

Underused PCR lab？BGI Sample Star-16 transforms it to a working colorectal cancer screening service - Client Story

Many PCR labs have the space, equipment, and skilled staff – but fluctuating testing demand leaves capacity idle.

A municipal hospital in China turned that underused lab into a daily colorectal cancer screening workflow using BGI Sample Star‑16 for automated nucleic acid extraction.

The result:
✅ Scalable throughput – ~26 samples/day with one technologist
✅ Operational consistency – automated pre‑analytical steps reduce manual variation
✅ Low recollect rate – only 10 of ~900 stool samples needed re‑testing
✅ Clinical impact – 12 of 15 colonoscopy‑positive cases detected adenomas

Key takeaway for labs:
Stool DNA methylation testing + automation turns existing PCR capacity into a sustainable, high‑value cancer prevention service.

📖 Read the full case study: https://www.bgi.com/global/news/bgi-sample-star-16-helps-pcr-labs-build-local-colorectal-cancer-screening-workflows

29/05/2026

On May 27, the American Cancer Society formally elevated multitarget stool DNA (mt-sDNA) tests to a preferred colorectal cancer ( ) screening modality for average‑risk adults starting at age 45, right before hashtag .

That means non‑invasive, accessible screening is no longer a nice-to-have – it's a priority.

' ™ (an mt‑sDNA test) has been validated in multiple studies:
- 91.5% sensitivity for CRC (Thailand prospective study)
- 96.1% sensitivity vs 85.8% for FIT (ASCO GI 2023)
- Already deployed in large‑scale public health programs in China (Harbin and Ordos) reaching millions.

Today is World Digestive Health Day. Perfect timing to refocus on early detection – because stage I CRC has a over 90% 5 year survival rate; but stage IV only 14%.

Early Screening Save Lives.

📖 Read how COLOTECT™ is leading the way: https://www.bgi.com/global/news/new-us-colorectal-cancer-screening-guidelines-prioritize-stool-dna-tests-bgi-genomics-colotect

28/05/2026

🩸🎗️Blood cancer – and in particular – is not one cancer. It's many.

Four main types (AML, ALL, CLL, CML) each have distinct biology and behavior. Even within the same type, molecular profiles vary widely.

That's why global guidelines recommend MICM (morphology, immunology, cytogenetics, and molecular biology). Only by seeing the full genomic picture can we guide precise, targeted intervention.

' SENTIS™ Leukemia Gene Detection delivers that molecular layer with two tailored options:
🔬 DNA+RNA – 373 genes + 1,000+ fusions (SNVs, InDels, CNVs, fusions)
🔬 DNA – 183 core genes for prognostic & hereditary risk

From newly diagnosed to relapse, pre‑transplant to remission monitoring – comprehensive genomics guides targeted therapy, risk stratification, and MRD tracking.

On today, Let's read it right.

👇 Learn more
https://www.bgi.com/global/news/bgi-genomics-sentis-leukemia-gene-detection-changing-leukemia-care

28/05/2026

📢 You're invited to join us at - 15th International Symposium on Antimicrobial Agents and Resistance

Antimicrobial resistance (AMR) is one of the most urgent global health threats. How can genomics help fight back?

📅Date: June 12–14, 2026
📌Venue: Hong Kong Convention and Exhibition Centre (HKCEC), Wanchai, Hong Kong
📍Booth D04

Discover how BGI Genomics' SIROmics™ AI-Powered Localized High-Throughput Sequencing Solution supports faster, smarter AMR detection and surveillance.

What SIROmics™ can offer:
🧬 High-throughput method for detecting hundreds to thousands of pathogens, including drug resistance and virulence genes.
🧬 Fully automated and intelligent NGS workflow solution for clinical labs
🧬 Actionable insights to guide treatment and infection control

👉 Register & learn more: https://www.isaar2026.org/

Come talk to our team. Let’s explore how AI-powered sequencing can strengthen your strategy.

See you in Hong Kong! 🇭🇰

27/05/2026

Meet Genos‑m: an ‑source DNA foundation model built for human‑associated microbes. 🧬🤖

BGI Genomics, BGI · Research and Zhejiang Lab just released Genos‑m – designed specifically for the microbial world inside and around us (commensals, pathogens, phages, across major body sites).

Open source (Apache 2.0) on and .

Why it matters:
✅ Sparse MoE architecture (4.7B params, only ~330M activated) – efficient & powerful
✅ 1 Mbp context – from short genes to whole genomes
✅ Outperforms or matches much larger general‑purpose models (even Evo2‑40B)
✅ Real‑world impact: colorectal cancer risk modelling, and stable embeddings from as few as 10,000 metagenomic reads

👇 More about the Genos-m model:
https://www.bgi.com/global/news/genos-m-is-now-open-source:-a-dna-foundation-model-for-human-associated-microbial-genomes

26/05/2026

In this talk from ICG21·RH 2026, Professor Thong Meow Keong of Universiti Tunku Abdul Rahman, , shares how countries have transformed their approach to rare diseases — from a fragmented, hospital-based response to a cohesive system rooted in national policy and multi-stakeholder collaboration.

He explains why rare diseases are now recognized as a issue, and how Malaysia is building a national committee focused not only on treatment, but also on prevention, rehabilitation, support, and research.

The Human Genome Project 2 ( ) will play a key role in supporting this vision — by correcting genomic data biases and enabling fairer, more inclusive healthcare systems grounded in shared global cooperation.

Professor Thong reminds us: every child deserves a second chance. Watch to learn how leadership, collaboration, and initiatives like HGP2 can improve health for all nations.

25/05/2026

Today is 🧬

Global thyroid cancer cases have risen 300% in three decades — now the 7th most common cancer worldwide. But here's the catch: better imaging is detecting more, not necessarily more disease.

Distinguishing the slow-growing tumors from aggressive ones and catching hereditary risks before they start will make a big difference.

' High-Throughput Sequencing solutions:
✅ SENTIS™ Hereditary Cancer Testing – for those with family history
✅ SENTIS™ Cancer+ Discovery – for confirmed patients needing targeted treatment

Incidence is rising. So is our ability to detect and treat with precision.

Read more:
https://www.bgi.com/global/news/world-thyroid-day-2026

Over the past three decades, global thyroid cancer incidence has risen by more than 300%, reaching an estimated 821,214 new cases in 2022, making it the seventh most common cancer worldwide. This dramatic rise is driven largely by advances in diagnostic im

25/05/2026

Busan, here we come! 🧬

We’re excited to join the Korean Society for Biochemistry and Molecular Biology ( ) International Conference 2026!

📍 Booth 103, 3F, BEXCO Convention Hall, Busan, Korea

🗓 May 27 (Wed) – May 29 (Fri)

This year’s event will gather around 2,500 attendees, bringing together researchers, innovators, and industry leaders from across the life science community. 🔬✨
Stop by our booth to explore:
✔ Multi-omics solutions
✔ Long-read sequencing services
✔ Spatial omics applications
✔ The latest technologies & research support

🎁 Don’t forget to pick up some exclusive goodies at our booth!

Whether you’re looking for new collaboration opportunities or simply want to talk science, we’d love to meet you in ! 👋

22/05/2026

Jiajia – “Happy Nut” and her sister’s gift

“At that time, I felt terrible inside. In the beginning, I really cried every single day.” Jiajia‘s mother said.

Jiajia was three months old when a township doctor saw her low haemoglobin but didn’t recognise thalassaemia. “He just told us to give her a blood transfusion.”

Two weeks later – after her condition worsened – she was finally diagnosed at Wuhan Children’s Hospital.

The family was poor. “BGI Genomics is really wonderful. They helped us with HLA matching for free back then. Our whole family was tested – it was all free of charge.”

Jiajia’s older sister became a haploidentical donor. Today, Jiajia is cured. She loves making new friends.

BGI Genomics provides free HLA typing to every family in need in China. That simple offer can transform a lifetime of transfusions into a cure.